Interferon-beta: Clinical Trials

7 trials of Interferon-beta, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 terminated, 1 withdrawn. 7 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 4, Terminated 2, Withdrawn 1
Phase 13Terminated 2, Completed 1

Follow Interferon-beta: new trials by email Literature Review of Interferon-beta trials Research Report on Interferon-beta

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis
Phase 2WithdrawnBiogen2021-06-302023-06-01
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Avelumab, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells - Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7
Phase 1 / Phase 2TerminatedFred Hutchinson Cancer Center82015-11-062022-03-22
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Aldesleukin, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells - Recurrent Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
Phase 1 / Phase 2TerminatedFred Hutchinson Cancer Center42013-02-012017-04-19
REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients
Interferon-beta and human leukocyte Interferon-α - Multiple Sclerosis
Phase 2CompletedMelinda Magyari102010-07-012012-11-30
Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II
Interferon Beta - Acute Lung Injury, Acute Respiratory Distress Syndrome
Phase 1 / Phase 2CompletedFaron Pharmaceuticals Ltd372009-02-012015-05-27
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
Cladribine, Placebo, Interferon-beta (IFN-beta) - Multiple Sclerosis
Phase 2CompletedEMD Serono Research & Development Institute, Inc.1722006-11-302020-10-12
Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
recombinant interferon beta - Stage IV Melanoma, Recurrent Melanoma
Phase 2CompletedCase Comprehensive Cancer Center212004-04-012015-10-02

Conditions studied

Carcinoma, Merkel Cell (2)  ·  Multiple Sclerosis (2)  ·  Acute Lung Injury (1)  ·  Melanoma (1)  ·  Respiratory Distress Syndrome (1)  ·  Uveal Melanoma (1)

Sponsors

Fred Hutchinson Cancer Center (2)  ·  Biogen (1)  ·  Case Comprehensive Cancer Center (1)  ·  EMD Serono Research & Development Institute, Inc. (1)  ·  Faron Pharmaceuticals Ltd (1)  ·  Melinda Magyari (1)

Countries

United States (4)  ·  Italy (1)  ·  Russia (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Aude Chapuis (2)  ·  Alan Davidson, MD (1)  ·  Alexander Binning, MD (1)  ·  Ernest C. Borden, MD (1)  ·  Geoff Bellingan, MD (1)  ·  Martin Kuper, MD (1)  ·  Martin Stotz, MD (1)  ·  Mathew Wise, MD (1)  ·  Melinda Magyari, M.D. (1)  ·  Richard Beale, MD (1)  ·  Timothy Walsh, MD (1)

Results publications

PMID 24503265, PMID 25877635, PMID 30027104, PMID 32447743

NIH funding

P30CA015704 (2), 2009 (1), 2019 (1), K24CA139052 (1), P30CA043703 (1), R01CA176841 (1)